RGDXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RGDXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-09-21), the Trailing Annual Dividend Yield of Response Genetics is 0.00%.
The historical rank and industry rank for Response Genetics's Dividend Yield % or its related term are showing as below:
Response Genetics's Dividend Payout Ratio for the three months ended in Mar. 2015 was 0.00.
As of today (2024-09-21), the Forward Dividend Yield % of Response Genetics is 0.00%.
Response Genetics's Dividends per Share for the three months ended in Mar. 2015 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Response Genetics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Response Genetics Quarterly Data | ||||||||||||||||||||
Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Dec15 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Diagnostics & Research subindustry, Response Genetics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Response Genetics's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Response Genetics (OTCPK:RGDXQ) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Response Genetics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Roberto Mignone | 10 percent owner | C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016 |
Bridger Management Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Swiftcurrent Offshore Ltd | 10 percent owner | C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
David Schreiber | director | 15 TROTTERS LANE, MONROE CT 06468 |
Sam Chawla | director | 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033 |
Van Den Broek Richard | director | 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
Kevin Roy Harris | officer: Vice President and CFO | 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210 |
Kirk K Calhoun | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Michael Serruya | director | C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033 |
Thomas A Bologna | director, officer: Chief Executive Officer | 4390 US ROUTE ONE, PRINCETON NJ 08540 |
Marxe Austin W & Greenhouse David M | 10 percent owner | C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Partners Swiftcurrent | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Bridger Capital Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Plc Glaxosmithkline | 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Michael A Metzger | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 12-14-2009
By gurufocus 10qk • 11-16-2009
By gurufocus • 05-15-2009
By gurufocus 10qk • 08-22-2009
By gurufocus 10qk • 05-14-2010
By gurufocus 10qk • 11-09-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.